ALSO NOTED: Halozyme inks tech pact; Bioniche gains SPA; Ariad shares on rise; and much more...

> Halozyme Therapeutics has agreed to put its technology to work to develop a new formulation of Baxter's Gammagard Liquid for subcutaneous delivery. Gammagard is used to treat primary immunodeficiency disorders and Baxter believes it could be more effective if delivered under the skin. Halozyme pockets $10 million upfront for the use of its Enhanze Technology in a pact worth a potential $47 million. Release

> Bioniche Life Sciences has hammered out a special protocol assessment agreement on a Phase III trial of its bladder cancer therapy. The pact clarifies the critical endpoints researchers will have to meet in order to gain an approval. Release

> Shares of Ariad Pharmaceuticals were on the rise this morning after the company announced a special protocol assessment deal with the FDA for oral deforolimus in patients with metastatic sarcomas. The drug is being developed with Merck. Report

> Lev Pharmaceuticals is touting positive results from a Phase III trial of Cinryze, a new therapy for hereditary angioedema. Release

> Endo Pharmaceuticals says that the FDA will make a decision on a new use for Frova by September 30. Release

> Merck has exercised an option for the exclusive use of Crucell's PER.C6 technology and an option for access to Crucell's AdVac vaccine technology in two infectious disease areas. Release

> Germany's MediGene has raised €15.6 million in a private placement. Release

> Anemia drugs just can't get a break. Now, the FDA is questioning whether the drugs--Amgen's Epogen and Aranesp and J&J's Procrit--actually improve kidney patients' quality of life. Report

> The atmosphere could be contentious when Bayer's Trasylol comes before an FDA advisory committee Wednesday. FiercePharma

> GlaxoSmithKline CEO Jean-Pierre Garnier struck back at critics over the weekend in an interview with London's Telegraph newspaper. He blamed a slide in the overall pharmaceuticals industry for the company's lackluster stock performance, which has drawn fire from investor groups. FiercePharma

And Finally… New research indicates that most people still behave pretty much like Neanderthals when it comes to choosing a mate. Release